Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Rheumatology

Day-to-Day Life and Long-term Health

At a Glance

Living with Nakajo-Nishimura syndrome requires specialist follow-up to balance inflammation control with medication safety. JAK inhibitor monitoring, physical and occupational therapy, kidney checks, vaccine precautions, and prompt attention to warning signs help protect health and mobility.

Living with Nakajo-Nishimura Syndrome (NNS) requires a shift from “treating a crisis” to “managing a lifestyle.” Because the condition is chronic and the medications are powerful, the goal of day-to-day care is to maintain a delicate balance: keeping inflammation low while protecting you or your child from the side effects of treatment [1].

A successful long-term plan involves a dedicated team of specialists—including rheumatologists, physical therapists, and sometimes nephrologists (kidney doctors)—working together to monitor progress [2].

Vigilant Monitoring on JAK Inhibitors

While JAK inhibitors like baricitinib are breakthroughs for NNS, they require a strict schedule of lab work to ensure they are working safely. The medical team will likely monitor the following markers on a regular schedule determined by the treating team [3][1]:

  • Viral Screening (BK Virus): In specific PRAAS cohorts, some centers may monitor for the BK polyomavirus [3]. While many people carry this virus without symptoms, it can become active when the immune system is suppressed, potentially affecting the kidneys [3]. Doctors use blood and urine tests to catch this early if clinically indicated [4].
  • Muscle and Blood Markers: If muscle symptoms warrant it, doctors may track creatine phosphokinase (CPK), an enzyme that can rise if muscles are inflamed or stressed by medication [4][5]. They also watch for anemia (low red blood cells), liver function, lipid levels, and changes in white blood cell counts [4][6].
  • Interferon Scores: Some specialized centers use an interferon-stimulated gene (ISG) score to see if the “volume” of the disease is truly being turned down at the cellular level [7][8].

Managing Movement and Strength

Because NNS causes progressive muscle loss (atrophy) and joint stiffness (contractures), physical and occupational therapy is often an important component of treatment [9][10].

The inflammation in NNS can cause the joints, especially in the fingers and wrists, to become fixed in a bent position [10]. A physical or occupational therapist can provide individualized care including:

  • Range-of-Motion Exercises: Gentle stretching to keep joints as flexible as possible [10].
  • Splinting: Using custom-made braces at night to help keep fingers straight and prevent contractures from worsening [1].
  • Strength Training: Gentle, consistent exercises to support the muscles in the upper body and trunk that are most affected by the disease [9].
  • Energy Conservation: Pacing strategies for dealing with fatigue.

Watching for AA Amyloidosis

A rare but serious long-term complication of uncontrolled inflammation in NNS is AA amyloidosis [11]. This happens when a protein called “amyloid” builds up in organs, most commonly the kidneys [11].

To monitor for this possibility, doctors perform regular urinalysis to look for proteinuria (protein in the urine) and check kidney function [11][1]. If you develop new swelling in the legs or face, it should be reported to your doctor immediately.

Red Flags: When to Seek Urgent Care

Because immunosuppressive medications change how the immune system works, certain symptoms require immediate evaluation by a specialist or an emergency department.

Seek medical attention immediately if you notice:

  • Signs of Severe Infection: A high fever that doesn’t go away, breathing difficulty, or a localized area of skin that is hot, red, and rapidly spreading [12][13].
  • Eye Pain or Redness: A red, painful eye, severe light sensitivity, or blurred vision, which could indicate keratitis or uveitis [14][15].
  • Vesicular Rash: A cluster of small blisters (like chickenpox or shingles), as these viruses can reactivate and spread quickly on JAK inhibitors [14][16].
  • Reduced Urine or Swelling: A sudden decrease in urination, or new puffiness/swelling around the eyes or ankles (potential signs of kidney stress or amyloidosis) [3][11].
  • Extreme Weakness or Pain: Sudden, severe muscle pain or an inability to move a limb that was previously functional [4][5].

Contact your specialist’s office the SAME DAY for:

  • A new or persistent fever (which could indicate a disease flare or a masked infection).

Managing the daily life of NNS is a marathon. By staying consistent with medications, avoiding live vaccines, and adhering to monitoring, you are taking the most important steps to protect long-term health and mobility [1].

Common questions in this guide

What monitoring is needed for NNS while taking a JAK inhibitor?
Your treating team may schedule blood and urine tests to check blood cell counts, liver function, lipid levels, and signs of infection. A muscle enzyme called creatine phosphokinase may be checked when muscle symptoms are present, and BK virus testing may be considered in certain situations. The exact schedule depends on your treatment and health.
How can physical or occupational therapy help someone with NNS?
Therapists can tailor gentle stretching, range-of-motion exercises, splints, strengthening, and pacing strategies to help preserve movement and manage fatigue. These measures are especially important when muscle loss or joint contractures make everyday activities harder.
How is kidney health monitored in Nakajo-Nishimura syndrome?
Doctors may use regular urine testing to look for protein and blood tests to assess kidney function. New swelling around the eyes or ankles, or a sudden decrease in urination, can signal kidney stress and should be reported promptly.
What are warning signs that require urgent care with NNS?
Seek immediate medical attention for trouble breathing, a persistent high fever, rapidly spreading hot or red skin, a painful red eye or vision changes, a blistering rash, sudden reduced urination or swelling, or severe weakness or muscle pain. These symptoms can reflect a serious infection, eye inflammation, kidney problem, or another complication.
Can people with NNS on immunosuppressive treatment receive vaccines?
Live vaccines may need to be avoided while taking immune-suppressing medicines because infections can reactivate or spread more easily. Ask the treating specialist which vaccines are appropriate and when they should be given, and do not change the medication plan without medical advice.
What should we do if someone with NNS develops a fever?
Contact the specialist’s office the same day for a new or persistent fever, because it may signal a flare or an infection that needs evaluation. Ask the care team in advance for a sick-day plan that explains who to call and whether any medicine should be held; do not make that decision on your own.

Get notified when new evidence is published on Nakajo-Nishimura syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.

    Cetin Gedik K, Lamot L, Romano M, et al.

    Annals of the rheumatic diseases 2022; (81(5)):601-613 doi:10.1136/annrheumdis-2021-221814.

    PMID: 35086813
  2. 2

    The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS.

    Cetin Gedik K, Lamot L, Romano M, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(5)):735-751 doi:10.1002/art.42087.

    PMID: 35315249
  3. 3

    JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.

    Sanchez GAM, Reinhardt A, Ramsey S, et al.

    The Journal of clinical investigation 2018; (128(7)):3041-3052.

    PMID: 29649002
  4. 4

    Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).

    Kanazawa N, Ishii T, Takita Y, et al.

    Pediatric rheumatology online journal 2023; (21(1)):38 doi:10.1186/s12969-023-00817-8.

    PMID: 37087470
  5. 5

    Symptomatic elevation creatine kinase following treatment of rheumatoid arthritis with baricitinib.

    Anjara P, Jiang M, Mundae M

    Clinical rheumatology 2020; (39(2)):613-614 doi:10.1007/s10067-019-04833-6.

    PMID: 31782014
  6. 6

    Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.

    Li W, Wang W, Wang W, et al.

    Frontiers in immunology 2022; (13()):825367 doi:10.3389/fimmu.2022.825367.

    PMID: 35418997
  7. 7

    Development of a Validated Interferon Score Using NanoString Technology.

    Kim H, de Jesus AA, Brooks SR, et al.

    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2018; (38(4)):171-185 doi:10.1089/jir.2017.0127.

    PMID: 29638206
  8. 8

    Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS.

    Cetin Gedik K, Ortega-Villa AM, Materne G, et al.

    Annals of the rheumatic diseases 2024; (83(9)):1181-1188 doi:10.1136/ard-2023-225463.

    PMID: 38653530
  9. 9

    Myositis with sarcoplasmic inclusions in Nakajo-Nishimura syndrome: a genetic inflammatory myopathy.

    Ayaki T, Murata K, Kanazawa N, et al.

    Neuropathology and applied neurobiology 2020; (46(6)):579-587 doi:10.1111/nan.12614.

    PMID: 32144790
  10. 10

    A Chinese case of Nakajo-Nishimura syndrome with novel compound heterozygous mutations of the PSMB8 gene.

    Jia T, Zheng Y, Feng C, et al.

    BMC medical genetics 2020; (21(1)):126 doi:10.1186/s12881-020-01060-8.

    PMID: 32513120
  11. 11

    Nakajo-Nishimura Syndrome: The First African Case.

    Ghodbane NE, Mecibah A, Merzougui Z, et al.

    Mediterranean journal of rheumatology 2023; (34(2)):262-265 doi:10.31138/mjr.34.2.262.

    PMID: 37654638
  12. 12

    JAK inhibitor therapy in CANDLE syndrome: a systematic review of clinical outcomes in 46 patients.

    Vahabi SM, Pourgholi E, Leblebici CB, et al.

    European journal of pediatrics 2026; (185(8)).

    PMID: 42547647
  13. 13

    Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.

    Sener S, Cam V, Ozen S, Batu ED

    Seminars in arthritis and rheumatism 2024; (66()):152426 doi:10.1016/j.semarthrit.2024.152426.

    PMID: 38442462
  14. 14

    PCR-confirmed severe geographic HSV-1 keratitis associated with systemic JAK inhibitor therapy.

    Roels D, Kreps EO, Houben I, et al.

    Journal of ophthalmic inflammation and infection 2026; (16(1)).

    PMID: 42176150
  15. 15

    From infection to infarction: cytomegalovirus retinitis complicated by retinal ischemia and vitreous hemorrhage in the setting of JAK inhibition - a case report.

    Johnson CD, El Zein L, Yamanuha J

    BMC ophthalmology 2026; (26(1)):20 doi:10.1186/s12886-025-04558-y.

    PMID: 41526852
  16. 16

    The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.

    Winthrop KL, Wouters AG, Choy EH, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(10)):1969-1977 doi:10.1002/art.40187.

    PMID: 28845577

This page is for informational purposes only and does not constitute medical advice. Monitoring, medication changes, and decisions about urgent care for Nakajo-Nishimura syndrome should be guided by your treating specialists.